OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
OHSU Knight Cancer Institute
CHU de Quebec-Universite Laval
Northwell Health
University of California, Davis
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
First Affiliated Hospital of Wenzhou Medical University
Poitiers University Hospital
University of Oklahoma
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Ruijin Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Memorial Sloan Kettering Cancer Center
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Columbia University
Dana-Farber Cancer Institute
University of California, Davis
Ruijin Hospital
Thomas Jefferson University
Thomas Jefferson University
University of Illinois at Chicago
Alliance for Clinical Trials in Oncology
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
China Medical University Hospital
Mayo Clinic
Abramson Cancer Center at Penn Medicine
Jinling Hospital, China
Abramson Cancer Center at Penn Medicine
OHSU Knight Cancer Institute
First People's Hospital of Hangzhou
Roswell Park Cancer Institute
Fudan University
Ruijin Hospital
Stanford University
Peking Union Medical College Hospital
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
University Hospitals Cleveland Medical Center
Shanghai Longyao Biotechnology Inc., Ltd.
University of Texas Southwestern Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Erasme University Hospital
University of Alabama at Birmingham
Case Comprehensive Cancer Center
AHS Cancer Control Alberta
PH Research, S.L.
University of Maryland, Baltimore